Name:Xuetao Cao
Sex:Male
Date of Birth:July 19, 1964
Nationality:Chinese
Marital Status:Married, 1 Child
Education:
1981. 8-1986. 6  M.D.   Second Military Medical University (Medicine)
1986. 8-1990.12 Ph. D. Department of Immunology, Second Military Medical University SMMU (Immunology)
Academic Appointments:
  1991. 1-1992. 12     Instructor in Immunology, Department of Immunology
  Second Military Medical University (SMMU), Shanghai, China
1992. 12-present        Professor in Immunology, Department of Immunology， SMMU, Shanghai
 1995. 10-2014.10       Chairman, Department of Immunology, SMMU
2000.4 –present        Director, Institute of Immunology, SMMU
2001.1 –present        Director, Institute of Immunology
                  Zhejiang University, Hangzhou, China
2004.6-2011.3        Vice-President, Second Military Medical University, Shanghai
2006.4-present       Director, National Key Laboratory of Medical Immunology of China, Shanghai, China
2011.3-2011.8         Vice-President, Chinese Academy of Medical Sciences, Beijing, China
2011.8- present       President, Chinese Academy of Medical Sciences, Beijing, China

 

Professional Societies:
Member, Chinese Academy of Engineering (2005.10-)
Foreign Member, German National Academy of Sciences (2013)
Foreign Member, French National Academy of Medicine (2014)
Foreign Member, EMBO (2015)
Past President, Federation of Immunological Societies of Asia-Oceania (FIMSA) (2012.3-2015.6)
Secretary General, Federation of Immunological Societies of Asia-Oceania (FIMSA) (2015.6-)
President, Global Alliance for Chronic Diseases (2014.1- present)
Past President, Chinese Society for Immunology (2006.11- 2014.10)
Secretary General, Chinese Society for Immunology (2014.10- present)
Member, American Association of Immunologists (1999-)
    Council member of 54th IUIS committee (2010-2013)
Chief Scientist, China National Program of Immunological Research (2001-present)
  
Editorial Board Members:
1994.12-present   Founder and Editor-in-chief, Chinese Journal of Cancer Biotherapy (In Chinese)
2004.1-present    Editorial Board, Cancer Immunology and Immunotherapy
2006.1-present    Associate Editor, Cancer Science
2007.1- present    Associate Editor, Gene Therapy
2007.1- present    Editorial Board, European Journal of Immunology
2007.7-present    Editorial Board, Cell Research
2007.7-2013.6    Editorial Board, Journal of Biological Chemistry
2008.1-present    Editorial board, International Immunopharmacology
2009.1-2012.6    Editorial board, Molecular Immunology
2009.1-2013.6    Editorial board, Journal of Immunology
2009.1-present    Editor-in-chief, Cellular and Molecular Immunology
2013.1-present    Associate Editor, Journal of Molecular Medicine
2013.1-present    Associate Editor, Cancer Immunology Research
2011.1-present,   Editorial Board, Science Translational Medicine
2011.1-present,   Editorial Board, Annual Reviews of Immunology
2013.9-present,   Editorial Board, Cell
2014.3-present,   Editorial Board, eLife
2014.10-present,  Associate Editor, Science Advances

 

Major Research Interests:
1.Innate signaling in infection and inflammation
2.Immune regulation
3. Tumor immunotherapy

 

Brief introduction:
Dr. Xuetao Cao is currently Professor and President of Chinese Academy of Medical Sciences. He was born in 1964, received his Ph.D. from Second Military Medical University (SMMU, Shanghai, China) in 1990. He became Professor in Immunology in 1992 and the Director of the Institute of Immunology in 2001 at the same University. He is now Professor and Director of China National Key Laboratory of Medical Immunology (2006.5-), and President of Chinese Academy of Medical Sciences (2011.8-). He was elected as member of Chinese Academy of Engineering in 2005. He had been President of Chinese Society for Immunology (2006.11-2014.10) for 8 years. He is now of Secretary General of Chinese Society for Immunology (2014.10-), President of FIMSA (Federation of Immunological Societies in Asia and Oceania) (2012.3-) and President of Global Alliance for Chronic Diseases (2014.1-). He is Editor-in-Chief of Cellular and Molecular Immunology, Associate Editor of Gene Therapy, Journal of Molecular Medicine, and editorial board member of Annual Reviews of Immunology, Cell, eLife, Science Translational Medicine, etc.
His major interests are innate signaling in infection and inflammation, immune regulation, tumor immunotherapy. He has made important contributions to the understanding of innate signaling in immunity and inflammation, identification of regulatory immune cell subsets and new immune molecules in immune response and cancer. His group has identified and functionally characterized 22 novel molecules from a human dendritic cell (DC) cDNA library. He identified several subsets of immune cells with regulatory function, for example, he found that splenic stroma can drive mature DC to further proliferate and differentiate into IalowCD11bhigh regulatory DC subset which can feedback inhibit immune response. This subset of regulatory DC can also drive generation of new regulatory immune cell subsets including immunosuppressive memory T cells (IL-4hiIL-10hiCD44hiCD62L-CCR7-) and regulatory B cells (IL-10hiCD19 hiFcgIIbhi), forming feedback loop for the control of immune response. He has identified important mediators and regulators of TLR/RIG-I-triggered innate inflammatory response. For example, he discovered E3 ligase Nrdp1/DRP from human DC cDNA library (1998) and then identified Nrdp1 as the enhancer of type I interferon production. He proposed that Siglec-G, mouse homolog of human Siglec-10 his lab independently cloned from human DC library, can selectively help RNA viruses escape innate immune response by promoting RIG-I degradation. He showed that membrane MHC-I and intracellular MHC-II molecules can negatively and positively regulate TLR-triggered response. He reported several microRNAs as regulators of type I interferon production and function, and recently identified lnc-DC in human DC differentiation proposed its new working mode by directly binding cytoplasmic signaling molecule STAT3. He screened and identified several candidates of biomarkers in the predication of cancer patients’ prognosis and responsiveness to immunotherapy, and also investigated new approaches to cancer immunotherapy in basic and clinic trial. As corresponding author, he published 226 original papers in peer-reviewed journals including Cell, Nature, Science, Nat Immunol, Cancer Cell, Immunity, J Exp Med, Nat Commun, PNAS, Blood, etc.

 

Selected publications:
1.Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, Zhao D, Liu Y, Wang C, Zhang X, Su X, Liu J, Ge W, Levine RL, Li N, Cao X. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015 Aug 19. doi: 10.1038/nature15252
2.Wang P, Xue Y, Han Y, Lin L, Wu C, Xu S, Jiang Z, Xu J, Liu Q, Cao X. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science. 2014 Apr 18;344(6181):310-3.
3.Liu J, Han C, Xie B, Wu Y, Liu S, Chen K, Xia M, Zhang Y, Song L, Li Z, Zhang T, Ma F, Wang Q, Wang J, Deng K, Zhuang Y, Wu X, Yu Y, Xu T, Cao X. Rhbdd3 controls autoimmunity by suppressing the production of IL-6 by dendritic cells via K27-linked ubiquitination of the regulator NEMO. Nat Immunol. 2014;15(7):612-22
4.Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K, Yang Y, Yang Y, Yang Y, Zhang Q, Zhu X, Li N, Wang Z, Ding G, Zhuang SM, Zheng L, Luo X, Xie Y, Liang A, Wang Z, Zhang M, Xia Q, Liang T, Yu Y, Cao X. Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell. 2014 Jan 13;25(1):49-63 (cover story)
5.Chen T, Yang M, Yu Z, Tang S, Wang C, Zhu X, Guo J, Li N, Zhang W, Hou J, Liu H, Han C, Liu Q, Gu Y, Qian C, Wan T, Cui L, Zhu M, Zheng W, Cao X. Small GTPase RBJ Mediates Nuclear Entrapment of MEK1/MEK2 in Tumor Progression. Cancer Cell. 2014 May 12; 25(5):682-96. (cover story)
6.Chen W, Han C, Xie B, Hu X, Yu Q, Shi L, Wang Q, Li D, Wang J, Zheng P, Liu Y, Cao X. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell. 2013;152(3):467-78
7.Xu S, Liu X, Bao Y, Zhu X, Han C, Zhang P, Zhang X, Li W, Cao X. Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps-SHP-2 pathway. Nat Immunol. 2012; 13(6):551-559
8.Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P, Yao H and Cao X. Intracellular MHC class II molecules promote TLR-triggered innate immuneresponses by maintaining activation of the kinase Btk. Nat Immunol, 2011, 12(5):416-424
9.Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M, Hua M, Li N, Yao H, Cao X. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ.Nat Immunol. 2011;12(9):861-869
10.Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang S, Zheng L, Liang A, Tao W, and Cao X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as a therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011, 19(2):232-243
11.Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y, Cao X. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol. 2010; 11(6):487-494
12.Han C, Jin J, Xu S, Liu H, Li N, Cao X. Integrin CD11b negatively regulates TLR-triggered inflammatory response by activating Syk and promoting MyD88 and TRIF degradation via cbl-b. Nat Immunol, 2010, 11(8):734-742
13.Wang C, Chen T, Zhang J, Yang M, Li N, Xu X, Cao X. The E3 ubiquitin ligase Nrdp1 preferentially promotes TLR-mediated type I interferon production. Nat Immunol, 2009, 10 (7): 744-752
14.An H, Hou J, Zhou J, Zhao Y, Xu H, Zheng Y, Yu Y, Liu S and Cao X. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting kinase IRAK-1. Nat Immunol, 2008, 9(5):542-550
15.An H, Zhao W, Hou J, Zhang Y, Xie Y, Zheng Y, Xu H, Qian C, Zhou J, Yu Y, Liu S, Feng G, Cao X. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity, 2006, 25: 919-928
16.Zhang M, Tang H, Guo Z, An H, Zhu X, Song W, Guo J, Huang X, Chen T, Wang J, Cao X.  Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells, Nat Immunol. 2004, 5(11):1124-1133  (cover story)